SQZ Biotechnologies Co (SQZ Biotechnologies Co) Financial Strength : 0 (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is SQZ Biotechnologies Co Financial Strength?

SQZ Biotechnologies Co has the Financial Strength Rank of 0.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

GuruFocus does not calculate SQZ Biotechnologies Co's interest coverage with the available data. As of today, SQZ Biotechnologies Co's Altman Z-Score is -23.02.

Competitive Comparison of SQZ Biotechnologies Co's Financial Strength

For the Biotechnology subindustry, SQZ Biotechnologies Co's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SQZ Biotechnologies Co's Financial Strength Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SQZ Biotechnologies Co's Financial Strength distribution charts can be found below:

* The bar in red indicates where SQZ Biotechnologies Co's Financial Strength falls into.

SQZ Biotechnologies Co Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

SQZ Biotechnologies Co's Interest Expense for the months ended in Sep. 2023 was $0.00 Mil. Its Operating Income for the months ended in Sep. 2023 was $-16.12 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $19.08 Mil.

SQZ Biotechnologies Co's Interest Coverage for the quarter that ended in Sep. 2023 is

GuruFocus does not calculate SQZ Biotechnologies Co's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

SQZ Biotechnologies Co's Debt to Revenue Ratio for the quarter that ended in Sep. 2023 is

Debt to Revenue Ratio	=	Total Debt (Q: Sep. 2023 )			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(2.397	+	19.075)	/	0
	=	N/A

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

SQZ Biotechnologies Co has a Z-score of -23.02, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

Warning Sign:

Altman Z-score of -23.02 is in distress zone. This implies bankruptcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SQZ Biotechnologies Co (OTCPK:SQZB) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

SQZ Biotechnologies Co has the Financial Strength Rank of 0.

SQZ Biotechnologies Co Financial Strength Related Terms

Thank you for viewing the detailed overview of SQZ Biotechnologies Co's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.

SQZ Biotechnologies Co (SQZ Biotechnologies Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SQZ Biotechnologies Co (OTCPK:SQZB) » Definitions » Financial Strength

Comparable Companies

Traded in Other Exchanges

N/A

Address

200 Arsenal Yards Boulevard, Suite 210, Watertown, MA, USA, 02472

Website

https://www.sqzbiotech.com

SQZ Biotechnologies Co is a clinical-stage biotechnology company developing transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. Using its proprietary technology, SQZ has the ability to deliver multiple materials into many patient cell types to engineer what it believes to be an unprecedented range of potential therapeutics for a range of diseases. The company has the potential to create well-tolerated cell therapies that can provide therapeutic benefit for patients and potentially improve the patient experience over existing cell therapy approaches, with accelerated production timelines under 24 hours and the elimination of preconditioning and lengthy hospital stays.

Executives

Richard Capasso	officer: See Remarks	C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Marshelle Smith Warren	officer: Chief Medical Officer	C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Klavs F. Jensen	director	C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Amy W Schulman	director, 10 percent owner	PFIZER INC. ATTN: CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Bernard Coulie	director	C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Vink Patrick V.j.j.	director	ETZELSTRASSE 20, 8707 UETIKON AM SEE V8 V8
Temasek Holdings (private) Ltd	10 percent owner	60B ORCHARD ROAD #06-18 TOWER 2, THE ATRIUM@ORCHARD, SINGAPORE U0 238891
Invus Public Equities, L.p.	10 percent owner	C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022
American International Group, Inc.	10 percent owner	1271 AVE OF THE AMERICAS, FL 37, NEW YORK NY 10020-1304
Polaris Entrepreneurs' Fund Vii, L.p.	10 percent owner	ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210
S.a. Westend	10 percent owner	VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Artal Group S.a.	10 percent owner	VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Arny Schulman, As Trustee The Armon R. Sharei Irrevocable Gst Trust Of 2016 U/d/t Dated December 29, 2016	10 percent owner	C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Marc Elia	director	C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Armon Sharei	director, officer: President and CEO	C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472